NCT03466294 2026-04-09
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
University of Colorado, Denver
Phase 2 Completed
Clinical Trials
77 trialsNCT02816021 2026-04-06
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT01787487 2026-03-31
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03264404 2026-01-27
Azacitidine and Pembrolizumab in Pancreatic Cancer
Columbia University
Phase 2 Completed
NCT01869114 2025-12-10
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT04266795 2025-10-21
PEVENAZA
Takeda
Phase 2 Completed
NCT02546986 2025-08-08
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT02269280 2025-08-07
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05662956 2025-07-15
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Hematology department of the 920th hospital
Phase 2 Completed
NCT02397720 2025-06-08
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01349959 2025-04-27
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04487106 2025-04-22
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03931291 2025-03-17
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
Phase 2 Completed
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT02807558 2024-12-13
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
Phase 2 Completed
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT03493646 2024-05-28
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
Phase 2 Completed
NCT01928576 2024-05-03
NA_00084192
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03572387 2024-04-30
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT05433532 2024-04-25
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT01812252 2024-02-15
ICT-HCT
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03542266 2023-08-22
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT04712942 2023-08-21
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
Phase 2 Completed
NCT04146038 2023-05-24
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02845297 2023-03-09
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02775903 2023-02-28
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
Phase 2 Completed
NCT05048615 2023-01-25
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Completed
NCT01700673 2022-10-18
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01845805 2022-10-04
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02610777 2022-09-19
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Takeda
Phase 2 Completed
NCT01168219 2022-08-04
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01462578 2021-11-15
RELAZA2
Technische Universität Dresden
Phase 2 Completed
NCT02497404 2021-09-22
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Weill Medical College of Cornell University
Phase 2 Completed
NCT03397173 2021-08-11
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01617226 2021-05-05
RAvVA
University of Birmingham
Phase 2 Completed
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT00813124 2021-02-11
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01912274 2021-02-09
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Helsinn Healthcare SA
Phase 2 Completed
NCT01180322 2020-12-31
azacitidine
University of Ulm
Phase 2 Completed
NCT01720225 2020-12-24
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03338348 2020-10-28
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
University of Ulm
Phase 2 Completed
NCT02458235 2020-10-12
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
Phase 2 Completed
NCT02472691 2020-05-28
AZALENA
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT00948064 2020-02-24
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02196857 2020-01-14
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02450877 2019-12-20
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
Celgene
Phase 2 Completed
NCT02017457 2019-12-10
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
University Hospital of Mont-Godinne
Phase 2 Completed
NCT01707004 2019-11-21
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Wisconsin, Madison
Phase 2 Completed